Horizon Pharma Public Limited Company (NASDAQ:HZNP) Logo Investors sentiment decreased to 0.86 in 2018 Q3. Its down 0.36, from 1.22 in 2018Q2. It dropped, as 25 investors sold Horizon Pharma Public Limited Company shares while 75 reduced holdings. 41 funds opened positions while 45 raised stakes. 134.96 million shares or 3.48% more from 130.42 million shares in 2018Q2 were reported.
Kopp Advsr Lc holds 92,189 shares. Ny State Common Retirement Fund stated it has 0.01% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Massachusetts Financial Services Ma invested in 0% or 109,972 shares. Profund Ltd Liability Company holds 0.02% or 30,907 shares in its portfolio. Brandywine Investment Management Ltd Com reported 0.3% stake. Aperio Gp Limited Liability Co invested in 0% or 18,288 shares. Systematic Mngmt Lp owns 70,180 shares or 0.03% of their US portfolio. California Employees Retirement Sys owns 286,114 shares or 0.01% of their US portfolio. Jpmorgan Chase accumulated 5.06 million shares. Moreover, Virtu Llc has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 11,236 shares. Voya Inv Mgmt Ltd Liability Company owns 67,236 shares. State Street stated it has 3.82M shares or 0.01% of all its holdings. Geode Capital Mgmt Ltd Limited Liability Company reported 1.78 million shares stake. Us Bancorp De has 63,794 shares for 0% of their portfolio. Principal Fin Gru has 0.01% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP).
Since August 16, 2018, it had 0 insider purchases, and 2 insider sales for $9.00 million activity. $8.80 million worth of stock was sold by Walbert Timothy P on Wednesday, November 14.
Analysts expect Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report $0.54 EPS on February, 27.They anticipate $0.25 EPS change or 86.21 % from last quarter’s $0.29 EPS. HZNP’s profit would be $90.51M giving it 9.46 P/E if the $0.54 EPS is correct. After having $0.65 EPS previously, Horizon Pharma Public Limited Company’s analysts see -16.92 % EPS growth. The stock increased 0.15% or $0.03 during the last trading session, reaching $20.44. About 1.04 million shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has risen 34.43% since January 30, 2018 and is uptrending. It has outperformed by 34.43% the S&P500. Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage
Among 4 analysts covering Horizon Pharma ( NASDAQ:HZNP ), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Horizon Pharma had 4 analyst reports since August 6, 2018 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, August 9. The firm earned “Market Perform” rating on Monday, August 6 by BMO Capital Markets. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, August 17 report. Mizuho downgraded the shares of HZNP in report on Thursday, November 15 to “Neutral” rating.
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $3.43 billion. The company’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Bizjournals.com which released: “Watertown biotech Selecta drops cancer drug, cuts staff – Boston Business Journal” on January 04, 2019, also Nasdaq.com with their article: “What’s in Store for Horizon Pharma (HZNP) in Q1 Earnings? – Nasdaq” published on May 07, 2018, Nasdaq.com published: “Horizon Pharma (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound? – Nasdaq” on December 07, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Globenewswire.com and their article: “Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout – GlobeNewswire” published on June 15, 2018 as well as Nasdaq.com ‘s news article titled: “Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy – Nasdaq” with publication date: January 02, 2019. Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart
Click here to view original web page at Analysts See $0.54 EPS for Horizon Pharma Public Limited Company (HZNP)